Merdury signs MOU with Health2Sync to conduct trial of Merdury’s StackDose technology intended for usage in GLP-1 (semaglutide) medication

TAIPEI, July 25, 2024 /PRNewswire/ — Merdury Biopharmaceutical Corporation (Merdury) (Taipei Exchange Stock Code: 6932) announced today that it has signed a Memorandum of Understanding (MOU) with Health2Sync, Asia’s largest chronic disease management platform. In this collaboration, the…